The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
March 28th 2024
The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Advanced Renal Cell Carcinoma
1.0 Credit / Oncology
View More
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
View More
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
View More
The Impact of Antibody-Drug Conjugates in Bladder Cancer and Gynecologic Malignancies
1.0 Credit / Oncology
View More
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
View More
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
View More
Exploring the Value of Pharmacist-Led Toxicity Management for New and Emerging Antibody-Drug Conjugates Across Solid Tumors
1.25 Credits / Oncology
View More
Improving Patient Outcomes in TNBC: Immunotherapy, PARP, TROP2, Oh My!
2.0 Credits / Oncology
View More
A Pharmacologic Overview of Antibody-Drug Conjugates
2.0 Credits / Oncology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Empowering Pharmacists to Improve Care for Patients with Myelofibrosis
1.0 Credit / Oncology
View More
Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Updates and Insights in Managing Anti-Androgen Therapies in Prostate Cancer
1.5 Credits / Oncology, Urology
View More
Improving Safety and Efficacy of Frontline Treatment Regimens in Advanced Hepatocellular Carcinoma
1.0 Credit / Oncology
View More
Exploring the Advancements in BTK Inhibitor Therapy for Mantle Cell Lymphoma and the Growing Impact of Oncology Pharmacists
1.0 Credit / Hematology, Oncology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Optimizing the Utilization of Targeted Therapies in CLL: Considerations and Insights for the Managed Care Professional
1.5 Credit / Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Improving the Delivery of CAR T-Cell Therapy for Multiple Myeloma
1.0 Credit / Oncology
View More
The Challenges of Chemotherapy Drug Shortages: The Oncology Pharmacist’s Perspective and Opportunities for Mitigation
1.0 Credit / Oncology
View More
Preparing for the Use of Multi-Cancer Early Detection Tests: Opportunities for Managed Care Professionals to Expand Cancer Screenings and Implement Early Clinical Intervention
1.5 Credits / Oncology
View More
Optimizing Safety and Utilization of Targeted Therapies in MET- or RET-Altered Non-Small Cell Lung Cancer
1.0 Credit / Oncology
View More
Non-Melanoma Skin Cancers: The Evolution of Treatment With Immune Checkpoint Inhibitors and Its Implications for Oncology Pharmacists
1.0 Credit / Oncology, Dermatology
View More
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More
Enfortumab Vedotin-ejfv, Pembrolizumab Combination Shows Promise Treating Urothelial Cancer
September 26th 2023Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.
Read More
Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma
September 22nd 2023Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.
Read More
Study Suggests Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia Treatment
September 14th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More
Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas
June 22nd 2023Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Read More
Axi-Cel Use in Patients With Large B-Cell Lymphoma Leads to Longer Overall Survival
June 16th 2023A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.
Read More
Targeting Folate Receptor Alpha Provides Therapeutic Benefits for Platinum-Resistant Ovarian Cancer
June 5th 2023Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.
Watch